CompletedNCT03379597
Official study titleA 12-weeks Study to Evaluate the Dietary Fiber and Probiotics Treatment in Prevention and Intervention of Weight-gain and Cognitive Impairment of Schizophrenia or Bipolar Disorder
This study has finished and is no longer accepting participants.
In ChangshaBipolarity, SchizophreniaMedication studyAges 18–65
- Countries
- China
- Sponsor
- Central South University
CompletedNCT03785223
Official study titleA 14 Week, Randomized, Placebo-Controlled Cross-Over Study of Methylphenidate Hydrochloride Controlled Release Capsules in Adult ADHD With and Without Anxiety Disorder Comorbidity
This study has finished and is no longer accepting participants.
In HamiltonAnxiety, ADHDMedication studyAges 18–65
- Countries
- Canada
- Sponsor
- McMaster University
CompletedNCT00261430
Official study titleSchizophrenia Treatment Acceptance Response Trial: a 20-week, Open-label, Multicenter, Randomized Study Comparing the Effect of the "GAIN Acceptance Approach Verses the "Approach-as-usual" in Supporting Patient Acceptance of Long-acting Risperidone (Risperdal� CONSTA�) in Adults With Schizophrenia
This study has finished and is no longer accepting participants.
Location not clearly listedSchizophreniaBehavioural studyAges 18–70
- Countries
- Sponsor
- Janssen, LP
TerminatedEUCTR 2011-001692-39
This study ended early.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In GermanyDepressionHistorical research record
- Countries
- Germany
- Sponsor
- Novartis Pharma GmbH
CompletedEUCTR 2008-002247-16
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In AustriaSchizophreniaHistorical research record
- Countries
- France, United Kingdom, Belgium, + 10 others
- Sponsor
- Janssen-Cilag International N.V.
CompletedEUCTR 2008-007483-42
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In Czech RepublicBipolarity, DepressionHistorical research record
- Countries
- France, Czechia, Germany, + 2 others
- Sponsor
- Sunovion Pharmaceuticals Inc.
CompletedEUCTR 2019-000737-39
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In BulgariaAddictionHistorical research record
- Countries
- Bulgaria, Croatia, Estonia, + 4 others
- Sponsor
- Adial Pharmaceuticals Inc.
TerminatedEUCTR 2021-006200-33
This study ended early.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In FinlandAddictionHistorical research record
- Countries
- Finland
- Sponsor
- Clairvoyant Therapeutics Inc.
CompletedNCT01714713
What is this study about?This study evaluated the safety of EVP-6124 for people with schizophrenia.
This study has finished and is no longer accepting participants.
Multiple locations, including Little RockSchizophreniaMedication studyAges 18–50
- Countries
- United States, Australia, Canada, + 13 others
- Sponsor
- FORUM Pharmaceuticals Inc
CompletedEUCTR 2016-001556-21
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In HungarySchizophreniaHistorical research record
- Countries
- Hungary
- Sponsor
- SUNOVION PHARMACEUTICALS INC.
CompletedEUCTR 2004-000751-42
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In GermanySchizophrenia, BipolarityHistorical research record
- Countries
- Germany
- Sponsor
- AstraZeneca AB
CompletedEUCTR 2012-003806-28
This study has finished and is no longer accepting participants.
Historical country statuses are shown below. They describe the trial's progress and do not confirm open recruitment.
In LatviaSchizophreniaHistorical research record
- Countries
- Latvia
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization,